Who
Sandra Pennell
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Delcath Systems.
In numbers
- Trades disclosed
- 11
- Buys
- 2
- Sells
- 0
- Bought
- $173K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 12 Jun 2023
- Last trade
- 6 Mar 2026
- Last filed
- 6 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Mar 2026filed 6 Mar 2026 | DCTH Delcath SystemsMedical Devices | SEC FORM 4 Bought | $50K5,533 at $9.04 | filing |
| 6 Mar 2026filed 6 Mar 2026 | DCTH Delcath SystemsMedical Devices | SEC FORM 4 Bought | $50K5,533 at $9.04 | filing |
| 17 Feb 2026filed 18 Feb 2026 | DCTH Delcath Systemsoption or derivative · Medical Devices | SEC FORM 4 Code A | —56,500 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | DCTH Delcath Systemsoption or derivative · Medical Devices | SEC FORM 4 Code A | —28,250 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | DCTH Delcath Systemsoption or derivative · Medical Devices | SEC FORM 4 Code A | —56,500 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | DCTH Delcath Systemsoption or derivative · Medical Devices | SEC FORM 4 Code A | —28,250 at $0.00 | filing |
| 7 Feb 2025filed 7 Feb 2025 | DCTH Delcath Systemsoption or derivative · Medical Devices | SEC FORM 4 Code A | —113,000 at $0.00 | filing |
| 19 Mar 2024filed 19 Mar 2024 | DCTH Delcath SystemsMedical Devices | SEC FORM 4 Code A | $100K26,881 at $3.72 | filing |
| 12 Feb 2024filed 14 Feb 2024 | DCTH Delcath Systemsoption or derivative · Medical Devices | SEC FORM 4 Code A | —100,500 at $0.00 | filing |
| 17 Nov 2023filed 21 Nov 2023 | DCTH Delcath SystemsMedical Devices | SEC FORM 4 Bought | $73K30,000 at $2.43 | filing |
| 12 Jun 2023filed 21 Jun 2023 | DCTH Delcath Systemsoption or derivative · Medical Devices | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
News
Delcath Systems, Inc.: Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal MelanomaDCTH · finanznachrichten.de · 19 Oct 2026Head-To-Head Analysis: Delcath Systems (NASDAQ:DCTH) & Neogen (NASDAQ:NEOG)DCTH · themarketsdaily.com · 18 Oct 2026Analyzing Green Thumb Industries (OTCMKTS:GTBIF) and Delcath Systems (NASDAQ:DCTH)DCTH · dailypolitical.com · 10 Oct 2026
0 headlines in the last 90 days name Sandra Pennell; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.